PMID- 23543570
OWN - NLM
STAT- MEDLINE
DCOM- 20130712
LR  - 20181221
IS  - 1469-493X (Electronic)
IS  - 1361-6137 (Linking)
IP  - 3
DP  - 2013 Mar 28
TI  - Methods for administering subcutaneous heparin during pregnancy.
PG  - CD009136
LID - 10.1002/14651858.CD009136.pub2 [doi]
AB  - BACKGROUND: Pregnant women with a history of venous thromboembolism (VTE), 
      antithrombin deficiency, or other risk factors for VTE, need heparin 
      (unfractionated heparin (UFH) or low-molecular weight heparin (LMWH)) 
      prophylaxis, mainly through administering subcutaneously. Several methods of 
      administering heparin (UFH or LMWH) subcutaneously have been introduced to 
      prevent adverse pregnant outcomes. The effectiveness and safety of different 
      methods administering subcutaneous heparin (UFH or LMWH) during pregnancy have 
      not been systematically evaluated. OBJECTIVES: To compare the effectiveness and 
      safety of different methods of administering subcutaneous heparin (UFH or LMWH) 
      to pregnant women. SEARCH METHODS: We searched the Cochrane Pregnancy and 
      Childbirth Group's Trials Register (31 January 2013) and reference lists of 
      retrieved studies. SELECTION CRITERIA: All randomised controlled trials 
      (individual and cluster) comparing the effectiveness and safety of different 
      methods of administering subcutaneous heparin (UFH or LMWH) during pregnancy. 
      Studies reported only as abstracts were eligible for inclusion and would have 
      been placed in studies awaiting assessment, pending the full publication of their 
      results. Quasi-randomised studies and cross-over trials were not eligible for 
      inclusion..Methods of administering subcutaneous heparin include intermittent 
      injections versus indwelling catheters or programmable (auto) external infusion 
      pumps, or any other devices to facilitate the subcutaneous administration of 
      heparin (UFH or LMWH) during pregnancy. DATA COLLECTION AND ANALYSIS: If eligible 
      trials had been identified, trial quality would have been assessed and data 
      extracted, unblinded by review authors independently. MAIN RESULTS: No trials met 
      the inclusion criteria for the review. AUTHORS' CONCLUSIONS: There is no evidence 
      from randomised controlled trials to evaluate the effectiveness and safety of 
      different methods of administering subcutaneous heparin (UFH or LMWH) to pregnant 
      women.
FAU - Sasaki, Hatoko
AU  - Sasaki H
AD  - Department of Health Policy, National Center for Child Health and Development, 
      Tokyo, Japan.
FAU - Yonemoto, Naohiro
AU  - Yonemoto N
FAU - Hanada, Nobutsugu
AU  - Hanada N
FAU - Mori, Rintaro
AU  - Mori R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
DEP - 20130328
PL  - England
TA  - Cochrane Database Syst Rev
JT  - The Cochrane database of systematic reviews
JID - 100909747
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Anticoagulants/*administration & dosage
MH  - Female
MH  - Heparin/*administration & dosage
MH  - Heparin, Low-Molecular-Weight/administration & dosage
MH  - Humans
MH  - Injections, Subcutaneous/methods
MH  - Pregnancy
MH  - Pregnancy Complications, Hematologic/*drug therapy
MH  - Venous Thromboembolism/*drug therapy
EDAT- 2013/04/02 06:00
MHDA- 2013/07/16 06:00
CRDT- 2013/04/02 06:00
PHST- 2013/04/02 06:00 [entrez]
PHST- 2013/04/02 06:00 [pubmed]
PHST- 2013/07/16 06:00 [medline]
AID - 10.1002/14651858.CD009136.pub2 [doi]
PST - epublish
SO  - Cochrane Database Syst Rev. 2013 Mar 28;(3):CD009136. doi: 
      10.1002/14651858.CD009136.pub2.